Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack

Recent clinical trials with chimeric antigen receptor (CAR) redirected T cells targeting CD19 revealed particular efficacy in the treatment of leukemia/lymphoma, however, were accompanied by a lasting depletion of healthy B cells. We here explored CD30 as an alternative target, which is validated in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Ther
Autores principales: Hombach, Andreas A, Görgens, André, Chmielewski, Markus, Murke, Florian, Kimpel, Janine, Giebel, Bernd, Abken, Hinrich
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5023391/
https://ncbi.nlm.nih.gov/pubmed/27112062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2016.82
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares